Literature DB >> 25543887

Optimizing signal intensity correction during evaluation of hepatic parenchymal enhancement on gadoxetate disodium-enhanced MRI: comparison of three methods.

Minori Onoda1, Tomoko Hyodo2, Takamichi Murakami3, Masahiro Okada4, Tatsuro Uto5, Masatoshi Hori6, Tosiaki Miyati7.   

Abstract

OBJECTIVE: To compare signal intensity (SI) correction using scale and rescale slopes with SI correction using SIs of spleen and muscle for quantifying multiphase hepatic contrast enhancement with Gd-EOB-DTPA by assessing their correlation with T1 values generated from Look-Locker turbo-field-echo (LL-TFE) sequence data (ER-T1).
MATERIALS AND METHODS: Thirty patients underwent Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in this prospective clinical study. For each patient, breath-hold T1-weighted fat-suppressed three-dimensional (3D) gradient echo sequences (e-THRIVE) were acquired before and 2 (first phase), 10 (second phase), and 20min (third phase) after intravenous Gd-EOB-DTPA. Look-Locker turbo-field-echo (LL-TFE) sequences were acquired before and 1.5 (first phase), 8 (second phase), and 18min (third phase) postcontrast. The liver parenchyma enhancement ratios (ER) of each phase were calculated using the SI from e-THRIVE sequences (ER-SI) and the T1 values generated from LL-TFE sequence data (ER-T1) respectively. ER-SIs were calculated in three ways: (1) comparing with splenic SI (ER-SI-s), (2) comparing with muscle SI (ER-SI-m), (3) using scale and rescale slopes obtained from DICOM headers (ER-SI-c), to eliminate the effects of receiver gain and scaling. For each of the first, second and third phases, correlation and agreement were assessed between each ER-SI and ER-T1.
RESULTS: In the first phase, all ER-SIs correlated weakly with ER-T1. In the second and third phases, ER-SI-c showed a stronger linear correlation with ER-T1 (r(2)=0.71-0.72, p<0.01) than did ER-SI-s (r(2)=0.37-0.39, p<0.01) or ER-SI-m (r(2)=0.30-0.41, p<0.01).
CONCLUSION: SI correction using scale and rescale slopes from DICOM data is the most acceptable algorithm for evaluating delayed-phase Gd-EOB-DTPA hepatic enhancement.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gadoxetate disodium; Liver function tests; Magnetic resonance imaging

Mesh:

Substances:

Year:  2014        PMID: 25543887     DOI: 10.1016/j.ejrad.2014.11.014

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Influence of Gd-EOB-DTPA on T1 dependence of the proton density fat fraction using magnetic resonance spectroscopy.

Authors:  Tatsuya Hayashi; Kei Fukuzawa; Hiroshi Kondo; Hiroshi Onodera; Rie Tojo; Shimpei Yano; Tosiaki Miyati; Jun'ichi Kotoku; Takahide Okamoto; Keiko Toyoda; Hiroshi Oba
Journal:  Radiol Phys Technol       Date:  2018-06-01

2.  Influence of Gd-EOB-DTPA on proton density fat fraction using the six-echo Dixon method in 3 Tesla magnetic resonance imaging.

Authors:  Tatsuya Hayashi; Kei Fukuzawa; Hiroshi Kondo; Hiroshi Onodera; Shuji Toyotaka; Rie Tojo; Shimpei Yano; Masakatsu Tano; Tosiaki Miyati; Jun'ichi Kotoku; Takahide Okamoto; Keiko Toyoda; Hiroshi Oba
Journal:  Radiol Phys Technol       Date:  2017-09-11

3.  A feasibility study evaluating the relationship between dose and focal liver reaction in stereotactic ablative radiotherapy for liver cancer based on intensity change of Gd-EOB-DTPA-enhanced magnetic resonance images.

Authors:  Sang Hoon Jung; Jeong Il Yu; Hee Chul Park; Do Hoon Lim; Youngyih Han
Journal:  Radiat Oncol J       Date:  2016-03-30

4.  Quantitative evaluation of focal liver lesions with T1 mapping using a phase-sensitive inversion recovery sequence on gadoxetic acid-enhanced MRI.

Authors:  Motohira Mio; Yasuhiro Fujiwara; Kazuki Tani; Tatsuo Toyofuku; Toshihiro Maeda; Toshiro Inoue
Journal:  Eur J Radiol Open       Date:  2020-12-24

5.  Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.

Authors:  Osman Öcal; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Kerstin Schütte; Antonio Gasbarrini; Ricarda Seidensticker; Moritz Wildgruber; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Eur Radiol       Date:  2021-08-31       Impact factor: 5.315

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.